×

Ohr Pharmaceutical to Report Second Quarter 2015 Financial and Business Results on Monday, May 11

NEW YORK, May 11, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the second quarter ended March 31, 2015 after the market close on Monday, May 11, 2015. The Company will also hold a live investor conference call and webcast at 5:00pm Eastern.

Conference Call & Webcast
Monday, May 11, 2015 at 5:00pm Eastern Time/2:00pm Pacific Time
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13609761
Webcast: http://public.viavid.com/player/index.php?id=114629
Replays – Available through May 25, 2015
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 13609761

About Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. is an ophthalmology research and development company whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several company-sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases. These diseases include wet-AMD, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.

CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 ir@ohrpharmaceutical.com LifeSci Advisors, LLC Michael Wood 646-597-6983 mwood@lifesciadvisors.comSource:Ohr Pharmaceutical, Inc.